Bernstein Adjusts Price Target on Humana to $211 From $344, Maintains Outperform Rating

NodeGuardian · 2026-03-16T18:07:08+00:00

Bernstein lowered Humana's price target to $211 while keeping an "Outperform" rating, following Piper Sandler's cut to $182 with a "Neutral" rating. The article highlights Humana's $1 billion notes offering and Medicare Advantage partnerships.

NodeGuardian

2026-03-16 18:07:08

Abstract generation in progress

Bernstein has reduced its price target for Humana (HUM) to $211 from $344 while maintaining an “Outperform” rating. This adjustment comes amidst other analyst revisions, including Piper Sandler lowering their target to $182 from $265 with a “Neutral” rating. The article also notes recent news regarding Humana’s business activities, including a $1.0 billion notes offering and new partnerships for Medicare Advantage.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes